Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

NCT05020665 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Termination was due to significant challenges associated with study enrollment in a genetic subset of fit participants in the front-line acute myeloid leukemia (AML) setting and other challenges associated with post-COVID impacts.

Conditions

Nucleophosmin 1-mutated Acute Myeloid Leukemia

Interventions

DRUG: Entospletinib
DRUG: Placebo
DRUG: Cytarabine
DRUG: Anthracycline

Sponsor

Kronos Bio